CRITICAL OUTCOME T COM NPV(POST REV SPLIT) (NASDAQ:COTQF) was downgraded by stock analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a research note issued to investors on Thursday.
Separately, Zacks Investment Research downgraded CRITICAL OUTCOME T COM NPV(POST REV SPLIT) from a “buy” rating to a “hold” rating in a research report on Monday, August 14th.
CRITICAL OUTCOME T COM NP (COTQF) opened at 0.8148 on Thursday. The stock has a 50 day moving average price of $0.25 and a 200 day moving average price of $0.22. The firm’s market cap is $13.20 million. CRITICAL OUTCOME T COM NP has a 52 week low of $0.83 and a 52 week high of $4.80.
TRADEMARK VIOLATION WARNING: This piece was first posted by Equities Focus and is the property of of Equities Focus. If you are accessing this piece on another website, it was copied illegally and reposted in violation of international trademark and copyright laws. The correct version of this piece can be viewed at https://www.equitiesfocus.com/2017/10/05/valuengine-lowers-critical-outcome-t-com-npvpost-rev-split-cotqf-to-strong-sell.html.
CRITICAL OUTCOME T COM NPV(POST REV SPLIT) Company Profile
Critical Outcome Technologies Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of cancer in Canada. The companys proprietary artificial intelligence platform, CHEMSAS, utilizes a series of predictive computer models to identify compounds from disease specific drug discovery through chemical optimization and preclinical testing.
Receive News & Ratings for CRITICAL OUTCOME T COM NPV(POST REV SPLIT) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRITICAL OUTCOME T COM NPV(POST REV SPLIT) and related companies with MarketBeat.com's FREE daily email newsletter.